Omedar (Omeprazole)

Omeprazole, the active ingredient in Omedar, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Omedar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omedar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics. - NSA‑induced gastropathy prophylaxis: lowers risk of ulcer formation in high‑risk patients.

Adverse reactions to omeprazole are generally mild to moderate, but serious events can occur.

Common Side Effects: - Headache: mild, transient headache. - Diarrhoea: loose stools, often self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Hypomagnesemia: low serum magnesium causing muscle cramps or cardiac arrhythmia. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use. - Vitamin B12 deficiency: reduced absorption leading to anemia.

When prescribing Omedar, clinicians should consider several safety aspects.

- Assess renal and hepatic function: adjust use if impairment is present. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Monitor long‑term users: watch for magnesium deficiency, bone health and vitamin B12 levels. - Counsel pregnant or breastfeeding patients: use only if clearly needed. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Omeprazole may interact with several medicines, altering their absorption or metabolism.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption leading to therapeutic failure. - HIV protease inhibitors (ritonavir, atazanavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Phenytoin: reduced serum levels, possibly decreasing seizure control. - Digoxin: increased concentrations, raising risk of toxicity.